Venous Thromboembolic Events in Cancer Patients

Problems vs Solution: Onco-Agulant app

Nadeen Galaleldin
Faculty of Pharmacy, Clinical Department

Aim:

The aim of “Onco-Agulant” is to deliver crucial and extensive information regarding “anticoagulants in cancer patients” to the healthcare professionals and to make the choice of the best anticoagulant for their patients an easy mission.

Methodology:

Onco-Agulant has 5 categories: VTE Prophylaxis, VTE treatment, reversal of anticoagulation, preoperative management, and heparin induced thrombocytopenia. The information was collected from NCCN 2022, summarized, organized, and added to in a mobile application under the supervision of a clinic Methodology.

The surveys were done in two ways: An online form using Google Forms platform and a real time survey through a visit to Al Miri Hospital. The online form was directed to a group of physicians, as well as the real time survey, which was done by two clinical pharmacists. In addition, a short introductory video was prepared and uploaded clarifying the proper use of our app.

Results:

By analyzing the reported responses, there was a significant decrease reported for both dose errors and interactions fatality. Different health care professionals reported different results related to its success in prescribing a prophylactic anticoagulant, thrombocytopenia management by the different risk scores mentioned in our app and also in perioperative management.

Conclusion:

After using Onco-Agulant we found that it aids in making the best treatment option with the least side effects avoiding the consequences and side effects of choosing the wrong anticoagulant. It also supported with all the possible cases to best accommodate all the patients.